Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. (Q52641201)

5 May 2018

title

Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. (English)

1 reference

5 May 2018

author name string

Michael W Jann

series ordinal

1

1 reference

5 May 2018

Scott R Penzak

series ordinal

2

1 reference

5 May 2018

publication date

22 March 2018

1 reference

5 May 2018

published in

CNS Drugs

1 reference

5 May 2018

volume

32

1 reference

5 May 2018

page(s)

241-257

1 reference

5 May 2018

issue

3

1 reference

5 May 2018

https://scigraph.springernature.com/pub.10.1007/s40263-018-0508-6

exact match

0 references

cites work

Blood flow in muscle groups and drug absorption

1 reference

12 December 2020

Clinical pharmacokinetics of the depot antipsychotics

1 reference

12 December 2020

Intramuscular preparations of antipsychotics: uses and relevance in clinical practice

1 reference

12 December 2020

Pharmacokinetic strategies in deciphering atypical drug absorption profiles

1 reference

12 December 2020

Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia

1 reference

12 December 2020

Intramuscular injection techniques

1 reference

12 December 2020

Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic

1 reference

12 December 2020

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

1 reference

12 December 2020

Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic

1 reference

12 December 2020

Antipsychotic long-acting injections: mind the gap

1 reference

12 December 2020

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

12 December 2020

Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration.

1 reference

12 December 2020

Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients

1 reference

12 December 2020

Intramuscular paliperidone palmitate

1 reference

12 December 2020

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

1 reference

12 December 2020

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

1 reference

12 December 2020

A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring

1 reference

12 December 2020

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

1 reference

12 December 2020

Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone

1 reference

12 December 2020

Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010.

1 reference

12 December 2020

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole

1 reference

12 December 2020

The pharmacokinetics of long-acting antipsychotic medications

1 reference

12 December 2020

Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective

1 reference

12 December 2020

Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study

1 reference

12 December 2020

Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis

1 reference

12 December 2020

A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia

1 reference

12 December 2020

Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics

1 reference

12 December 2020

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial

1 reference

12 December 2020

Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study

1 reference

12 December 2020

Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia

1 reference

12 December 2020

Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management

1 reference

12 December 2020

Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole

1 reference

12 December 2020

Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug

1 reference

12 December 2020

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial

1 reference

12 December 2020

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice

1 reference

12 December 2020

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?

1 reference

12 December 2020

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

1 reference

12 December 2020

Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia

1 reference

12 December 2020

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials

1 reference

12 December 2020

Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia

1 reference

12 December 2020

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

1 reference

12 December 2020

Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration

1 reference

12 December 2020

Proposing the Use of Partial AUC as an Adjunctive Measure in Establishing Bioequivalence Between Deltoid and Gluteal Administration of Long-Acting Injectable Antipsychotics.

1 reference

12 December 2020

Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

1 reference

12 December 2020

Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia

1 reference

12 December 2020

Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia

1 reference

12 December 2020

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence

1 reference

12 December 2020

Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia

1 reference

12 December 2020

Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study

1 reference

12 December 2020

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being

1 reference

12 December 2020

Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study

1 reference

12 December 2020

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration

1 reference

12 December 2020

The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole

1 reference

12 December 2020

Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data

1 reference

12 December 2020

Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation

1 reference

12 December 2020

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia

1 reference

12 December 2020

Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores

1 reference

12 December 2020

Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study

1 reference

12 December 2020

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole

1 reference

12 December 2020

Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia

1 reference

12 December 2020

Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model

1 reference

12 December 2020

Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.

1 reference

12 December 2020

Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.

1 reference

12 December 2020

Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations

1 reference

12 December 2020

Converting oral to long-acting injectable antipsychotics: a guide for the perplexed.

1 reference

12 December 2020

Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia.

1 reference

12 December 2020

10.1007/S40263-018-0508-6

Identifiers

DOI

1 reference

5 May 2018

PubMed ID

29569082

1 reference

5 May 2018